SCP
DNLI icon

Syntal Capital Partners’s Denali Therapeutics DNLI Stock Holding History

Syntal Capital Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,408
Closed -$2.29K – 125
2020
Q4 		$2.29K Buy
+27,408
New +$1.66M 0.29% 22

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Syntal Capital Partners's DNLI Position: Q1 2021 in Review

Syntal Capital Partners sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 27,408 shares — an estimated $2.29K sold.

Syntal Capital Partners first reported a position in DNLI in Q4 2020 and held it in 1 quarter. The position peaked at $2.29K in Q4 2020. 217 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

  • Syntal Capital Partners reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Syntal Capital Partners sold 27,408 Denali Therapeutics shares in Q1 2021, an estimated $2.29K.
  • Syntal Capital Partners first reported a position in Denali Therapeutics in Q4 2020 and held it in 1 quarter.
  • Syntal Capital Partners's Denali Therapeutics position peaked at $2.29K in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on Syntal Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.